Aptose Biosciences to Present at Canaccord Genuity 38th Annual Growth Conference

On August 2, 2018 Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, reported that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the Canaccord Genuity 38th Annual Growth Conference being held from Wednesday, August 8th to Thursday, August 9th, 2018, at the Intercontinental Hotel, Boston, MA (Press release, Aptose Biosciences, AUG 2, 2018, View Source;p=RssLanding&cat=news&id=2361651 [SID1234528373]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction.

Time: 12:30 p.m. ET
Date: Thursday, August 9, 2018
Location: Intercontinental Hotel, Boston, MA
A live webcast of the Aptose presentation will be accessible by visiting:

View Source

The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com